STOCK TITAN

Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into 213,771-share stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LEXICON PHARMACEUTICALS director Sam L. Barker exercised restricted stock units into common shares. On 2026-06-03, 89,312 restricted stock units converted into 89,312 shares of common stock at a stated price of $0.00 per share, reflecting equity compensation rather than an open‑market trade.

Following this conversion, Barker directly owns 213,771 shares of common stock. The footnotes explain that each restricted stock unit represented a contingent right to receive one share of common stock, and that the award vested in full on the first anniversary of its grant date.

Positive

  • None.

Negative

  • None.
Insider BARKER SAM L
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 89,312 $0.00 --
Exercise Common Stock 89,312 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 213,771 shares (Direct, null)
Footnotes (1)
  1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock.
RSUs exercised 89,312 units Restricted stock units converted to common stock on 2026-06-03
Common shares received 89,312 shares Shares of common stock issued upon RSU conversion
Post-transaction holdings 213,771 shares Common stock directly owned after RSU exercise
Exercise price per share $0.00/share Stated price for RSU conversion into common stock
Restricted Stock Units financial
"The footnotes explain that each restricted stock unit represented a contingent right to receive one share of common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share of common stock"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BARKER SAM L

(Last)(First)(Middle)
2445 TECHNOLOGY FOREST BLVD.
11TH FLOOR

(Street)
THE WOODLANDS TEXAS 77381

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/03/2026M89,312A$0213,771D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$006/03/2026M89,312 (1) (2)Common Stock89,312$00D
Explanation of Responses:
1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
2. Each restricted stock unit represents a contingent right to receive one share of common stock.
/s/ Samuel L. Barker06/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Sam L. Barker report for LEXICON PHARMACEUTICALS (LXRX)?

Sam L. Barker reported exercising 89,312 restricted stock units into common stock. The units converted to 89,312 shares at a stated price of $0.00 per share, reflecting an equity compensation event rather than an open‑market purchase or sale.

How many LEXICON PHARMACEUTICALS (LXRX) shares does Sam L. Barker hold after this Form 4?

After the transaction, Sam L. Barker directly holds 213,771 shares of Lexicon Pharmaceuticals common stock. This figure reflects his position following the conversion of 89,312 restricted stock units into common shares reported in the Form 4 filing.

What security did Sam L. Barker convert in the Lexicon Pharmaceuticals (LXRX) Form 4?

He converted restricted stock units into common stock. Specifically, 89,312 restricted stock units, each representing a contingent right to receive one share, were exercised and settled into 89,312 shares of Lexicon Pharmaceuticals common stock.

Was Sam L. Barker’s Lexicon Pharmaceuticals (LXRX) Form 4 transaction a market buy or sell?

No, it was not a market buy or sell. The Form 4 shows a derivative exercise, where 89,312 restricted stock units converted into common stock at $0.00 per share as part of equity compensation, with no reported open‑market purchase or sale.

How did the restricted stock units in Lexicon Pharmaceuticals (LXRX) vest for Sam L. Barker?

The restricted stock units vested 100% on the first anniversary of their grant date. Each unit represented a contingent right to receive one share of Lexicon Pharmaceuticals common stock, and the vested units were then converted into 89,312 common shares.